AltMountain

Empery Asset Management, LP

New York City, NY · CRD 148180
Hedge fund manager

Empery Asset Management, LP is an SEC-registered investment adviser based in New York City, NY that reports managing 4 hedge funds on Form ADV. It reports $262.5 million in regulatory assets under management. Its private funds, of all types, hold $262.5 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +11.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +11.3% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.

Regulatory assets under management
$262.5 millionForm ADV Item 5.F
Gross assets of private funds
$262.5 millionAll private fund types, Form ADV
Hedge funds managed
44 private funds in total
Employees
6Form ADV Item 5.A
Registration
SEC-registered adviserCRD 148180
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+11.3%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 quarters+11.3%Q1 2026 – Q2 2026
S&P 500+9.5%Same quarters, price only
13F holdings$86.5 million32 positions, 2026-06-30
$95$103$111Q1 2026Q2 202613F est. $111S&P 500 $110
QuarterEst. 13F returnS&P 500
Q2 2026+9.0%+14.8%
Q1 2026+2.1%-4.6%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 32 share positions ($81,410,092) reported by Empery Asset Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • X4 Pharmaceuticals Inc34.64%
  • Empery Digital Inc17.86%
  • Outlook Therapeutics Inc14.97%
  • Nervgen Pharma Corp7.76%
  • Cleancore Solutions Inc3.19%
  • Pyxis Oncology Inc2.86%
  • Cellectar Biosciences Inc2.16%
  • Amylyx Pharmaceuticals Inc2.14%
  • Dyadic Intl Inc Del1.83%
  • Tenaya Therapeutics Inc1.58%
StockValue% of 13F portfolioSharesShares vs prior quarter
X4 Pharmaceuticals Inc$28,203,97634.64%9,725,509+40.33%
Empery Digital Inc$14,539,33817.86%4,830,345+64.84%
Outlook Therapeutics Inc$12,185,64514.97%21,247,856New
Nervgen Pharma Corp$6,320,1387.76%3,308,973-17.28%
Cleancore Solutions Inc$2,598,0003.19%20,000,000New
Pyxis Oncology Inc$2,330,0002.86%1,000,000New
Cellectar Biosciences Inc$1,757,4172.16%955,118+403.74%
Amylyx Pharmaceuticals Inc$1,746,0002.14%60,000New
Dyadic Intl Inc Del$1,487,7541.83%3,346,275New
Tenaya Therapeutics Inc$1,284,8991.58%2,128,726-44.90%
Greenland Energy Co$1,170,0001.44%1,000,000Unchanged
Femasys Inc$1,012,5001.24%468,750New
Cyngn Inc$982,6851.21%1,310,422-5.76%
Quoin Pharmaceuticals LTD$934,3901.15%204,910New
Clene Inc$904,3731.11%221,660-75.82%
Ur-energy Inc$669,7470.82%620,136Unchanged
Precision Biosciences Inc$640,3480.79%102,292-86.82%
Lantern Pharma Inc$548,7700.67%543,337-35.52%
Satellos Bioscience Inc$493,0000.61%58,000-45.85%
One And One Green Technologi$443,0060.54%311,976-59.04%
Jaguar Uranium Corp$373,2260.46%345,580-29.11%
Briacell Therapeutics Corp$348,0000.43%300,000Unchanged
Gossamer Bio Inc$295,7050.36%24,954New
Duke Robotics Corp$52,1500.06%35,000Unchanged
Renatus Tactical Acquis$27,0000.03%50,000Unchanged
Maris Tech LTD$20,8620.03%297,600Unchanged
Spectral Ai Inc$15,6680.02%33,336Unchanged
Cea Industries Inc$10,7600.01%500,000Unchanged
Nexera Technologies LTD$5,3370.01%360,577Unchanged
Neurosense Therapeutics LTD$4,2970.01%95,499-4.88%
Fgi Industries LTD$4,0030.00%83,928Unchanged
Nexgel Inc$1,0980.00%90,000Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 8 new positions, 8 sold out, 3 increased, 10 reduced and 11 unchanged.

Number of positions (a count, not dollars)

  • New positions8
  • Increased3
  • Unchanged11
  • Reduced10
  • Sold out8

New positions

StockValueShares
Outlook Therapeutics Inc$12,185,64521,247,856
Cleancore Solutions Inc$2,598,00020,000,000
Pyxis Oncology Inc$2,330,0001,000,000
Amylyx Pharmaceuticals Inc$1,746,00060,000
Dyadic Intl Inc Del$1,487,7543,346,275
Femasys Inc$1,012,500468,750
Quoin Pharmaceuticals LTD$934,390204,910
Gossamer Bio Inc$295,70524,954

Sold out

StockValue at Jun 30, 2026Shares held then
Annovis Bio Inc$4,466,7452,401,476
Amc Entmt Hldgs Inc$3,256,6821,714,043
Venu Hldg Corp$1,164,097512,818
Scynexis Inc$514,656126,451
Rein Therapeutics Inc$385,667370,834
BTC Digital LTD$288,912350,877
Parazero Technologies LTD$55,338113,771
Nutriband Inc$40,21840,218

Largest increases

StockChange in sharesChangeValue nowShares now
X4 Pharmaceuticals Inc+2,794,918+40.33%$28,203,9769,725,509
Empery Digital Inc+1,900,000+64.84%$14,539,3384,830,345
Cellectar Biosciences Inc+765,513+403.74%$1,757,417955,118

Largest reductions

StockChange in sharesChangeValue nowShares now
Precision Biosciences Inc-673,801-86.82%$640,348102,292
Clene Inc-694,872-75.82%$904,373221,660
Nervgen Pharma Corp-691,027-17.28%$6,320,1383,308,973
Tenaya Therapeutics Inc-1,734,389-44.90%$1,284,8992,128,726
One And One Green Technologi-449,730-59.04%$443,006311,976
Satellos Bioscience Inc-49,100-45.84%$493,00058,000
Lantern Pharma Inc-299,332-35.52%$548,770543,337
Jaguar Uranium Corp-141,920-29.11%$373,226345,580
Cyngn Inc-80,166-5.76%$982,6851,310,422
Neurosense Therapeutics LTD-4,903-4.88%$4,29795,499

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Annovis Bio, Inc.13G amendment4.99%2,241,537Oct 15, 2026SEC.gov ↗
Femasys Inc.13G5.6%468,750Oct 15, 2026SEC.gov ↗
Dyadic International Inc.13G8.35%3,346,275Oct 15, 2026SEC.gov ↗
Lantern Pharma Inc.13G amendment4.99%755,891Oct 13, 2026SEC.gov ↗
Clene Inc.13G amendment1.56%221,660Oct 13, 2026SEC.gov ↗
Outlook Therapeutics, Inc.13G8.73%21,247,856Oct 13, 2026SEC.gov ↗
Empery Digital Inc.13D amendment17.15%4,830,345Sep 3, 2026SEC.gov ↗
Cellectar Biosciences, Inc.13G9.99%864,090Aug 4, 2026SEC.gov ↗
Abits Group Inc.13G amendment0%0Jul 29, 2026SEC.gov ↗
Super League Enterprise, Inc.13G amendment4.99%85,909Jul 29, 2026SEC.gov ↗
Precision BioSciences, Inc.13G amendment4.99%1,314,393Jul 29, 2026SEC.gov ↗
Cyngn Inc.13G9.99%1,404,049Apr 22, 2026SEC.gov ↗
Imperial Petroleum Inc.13G amendment4.99%2,298,892Apr 15, 2026SEC.gov ↗
Robin Energy Ltd.13G amendment0%0Apr 15, 2026SEC.gov ↗
Immuneering Corp13G amendment4.99%3,250,775Jan 15, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Oct 21, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 19 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (5)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (4)

Fund
Gross assets
Minimum
Owners
Adviser
Empery Asset Master, LTD
Cayman IslandsHedge fund
Gross assets$59.1M
Minimum$1.0M
Owners51
AdviserEmpery Asset Management, LP
Empery Debt Opportunity Fund, LP
Delaware, United StatesHedge fund
Gross assets$36.5M
Minimum$100K
Owners3
AdviserEmpery Asset Management, LP
Empery Tax Efficient III, LP
Delaware, United StatesHedge fund
Gross assets$24.1M
Minimum$1.0M
Owners2
AdviserEmpery Asset Management, LP
Empery Tax Efficient, LP
Delaware, United StatesHedge fund
Gross assets$17.2M
Minimum$250K
Owners46
AdviserEmpery Asset Management, LP

As reported in the adviser's Form ADV filed Mar 29, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌​‌⁠